Ubiquitination modifications as central regulators of metabolic dysfunction in type 2 diabetes mellitus - Report - MDSpire

Ubiquitination modifications as central regulators of metabolic dysfunction in type 2 diabetes mellitus

  • By

  • Wen-tao Wang

  • Ze-ya Shi

  • Hai-long Wang

  • Zhao-yang Chen

  • July 9, 2026

  • 0 min

Share

Clinical Report: The Role of Ubiquitination Modifications in Regulating Metabolic Dysfunction in Type 2 Diabetes Mellitus

Overview

This review highlights the role of ubiquitination in the pathogenesis of Type 2 diabetes mellitus (T2DM), emphasizing the involvement of E3 ubiquitin ligases and deubiquitinating enzymes in metabolic regulation.

Background

Type 2 diabetes mellitus is a significant global health issue characterized by insulin resistance and pancreatic β-cell dysfunction. The increasing prevalence of T2DM, driven by genetic and environmental factors, necessitates a deeper understanding of its underlying mechanisms. Ubiquitination has emerged as a key post-translational modification that regulates protein stability and activity, influencing metabolic processes and disease progression.

Data Highlights

No specific numerical data or trial results were provided in the source material.

Key Findings

  • Ubiquitination is a central regulator of cellular homeostasis and metabolic dysfunction in T2DM.
  • E3 ubiquitin ligases and deubiquitinating enzymes (DUBs) play crucial roles in the stability and activity of signaling proteins in insulin-sensitive tissues.
  • The review identifies specific E3 ligases and DUBs with defined pathological functions in T2DM.
  • Multi-omics approaches and AI platforms are suggested as future directions for accelerating translational applications in T2DM research.

Clinical Implications

Understanding the role of ubiquitination in T2DM may lead to the development of targeted therapies that address metabolic dysfunction.

Conclusion

The review highlights the role of ubiquitination in T2DM pathology.

Related Resources & Content

  1. Frontiers in Endocrinology, 2026 -- Ubiquitination modifications as central regulators of metabolic dysfunction in type 2 diabetes mellitus
  2. Frontiers in Endocrinology — Cellular senescence and metabolic aging in type 2 diabetes: mechanistic insights and translational implications
  3. Frontiers in Endocrinology — Regulatory networks of post-translational modifications in diabetic kidney disease: from pathogenic mechanisms to therapeutic frontiers
  4. Frontiers in Endocrinology — From mechanisms to therapies: exploiting epigenetic and post-translational modifications of mitochondrial quality control in diabetic kidney disease
  5. The Journal of Clinical Endocrinology & Metabolism — Emerging Strategies for Preventing Type 2 Diabetes
  6. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026 | Diabetes Care | American Diabetes Association
  7. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes - PubMed
  8. Frontiers | Ubiquitination modifications as central regulators of metabolic dysfunction in type 2 diabetes mellitus

Original Source(s)

Ubiquitination modifications as central regulators of metabolic dysfunction in type 2 diabetes mellitus

  • by Wen-tao Wang, Ze-ya Shi, Hai-long Wang, Zhao-yang Chen

  • July 9, 2026

Related Content

Gonadotropin therapy in idiopathic hypogonadal non-obstructive azoospermia (APHRODITE Groups 3–4): a multicenter randomized controlled trial

Investigating the association between low-density lipoprotein cholesterol/high-density lipoprotein cholesterol and the risk of carotid artery plaque in patients with first-ever ischemic stroke based on different glucose metabolic conditions

Evaluating the role of youth-onset diabetes mellitus in the context of food insecurity and preventive care: a repeated cross-sectional study using propensity score weighted machine learning analysis